NanoTherm™
NanoActivator®
Risks & Benefits
What are the Potential Benefits of Participating?
In the next stage of the Clinical Study, the potential benefits to the patient is the prostate cancer is effectively ablated with minimal side effects. We expect the clinical trial will prove that NanoTherm™ therapy will allow men diagnosed with intermediate-risk prostate cancer to have a higher quality of life, while delaying or even avoiding definitive treatments.
What are Some of the Possible Risks of Participating?
There are risks to taking part in any research study. There is a risk the NanoTherm™ particles and treatment may cause problems (side effects), which may be mild or very serious. The injection of the nanoparticles into your prostate may result in bleeding, infection, or inflammation – but these are uncommon side effects. The side effects that other people have experienced so far with the treatment are: sweating, mild discomfort, skin irritation or burning as well as an increase of body temperature, blood pressure and heart rate.
Are All of the Potential Risks Known?
It is important to note that the NanoTherm™ technology is still investigational for use in ablating prostate cancer tissue, so all the potential side effects are still unknown at this point. In fact, this is one of the main reasons that MagForce is currenting undertaking this Clinical Study -- to study its safety in the treatment of prostate cancer.
How Can I Learn More About the Potential Risks?
Prior to participating in the clinical study, all potential subjects will have a meeting with one of the our principal investigators of the study. This initial meeting will help you learn more about the clinical trial -- and help answer any questions you might have. Prior to enrolling in the study, you would be asked to review and sign an “Informed Consent” – which goes into much more detail of the patient health risks or problems. The principal investigator will be available to answer any questions that you might have about all known and potential risks.